Literature DB >> 2095568

Cytotoxicity of three novel fluoropyrimidines in cultured L1210 murine lymphocytic leukemia cells.

A M Shipp1, M H Holshouser, P W Ferguson.   

Abstract

Cultured L1210 murine lymphocytic leukemia cells were used to compare metabolic activation and cytotoxicity of 5-fluorouracil (FU), Ftorafur (FT), and three novel FU-sulfur analogues. These analogues, 1-(2'-tetrahydrothienyl)-5-fluorouracil (FUS), 1-(2'-tetrahydrothienyl)-5- fluorouracil-1'-oxide (FUSO), and 1-(2'-tetrahydrothienyl)-5-fluorouracil-1'-1'-dioxide (FUSO2), have yet to be fully evaluated for potential therapeutic value based on in vitro cytotoxicity. The role of these FU analogues as prodrugs was evaluated by comparing metabolism of normal pyrimidine pathways and activation by hepatic mixed function oxidases (MFO). Significant differences in biochemical activity and cytotoxicity were measured between FU and FU analogues. FU and FU analogues were cytotoxic to L1210 cells (63-92% growth inhibition of 100 microM concentrations after 72 hr of incubation). However, at equimolar concentration cytotoxicity of the FU analogues after MFO activation (56-66% growth inhibition) was greater than FU (47% growth inhibition). Hypoxanthine, a purine precursor, did not significantly alter fluoropyrimidine cytotoxicity with or without MFO. Thymidine and uridine, pyrimidine precursors, reduced FT and FUS cytotoxicities in the presence (27, 40%) and absence (25, 15%) of MFO but did not modify FU, FUSO, or FUSO2 cytotoxicities.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095568     DOI: 10.1023/a:1015998107767

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  20 in total

1.  The disposition of ftorafur in rats after intravenous administration.

Authors:  A M Cohen
Journal:  Drug Metab Dispos       Date:  1975 Jul-Aug       Impact factor: 3.922

Review 2.  Fluorinated pyrimidines and their nucleosides.

Authors:  C Heidelberger; P V Danenberg; R G Moran
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1983

3.  Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes.

Authors:  Y M El Sayed; W Sadée
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

4.  Prevention of antitumor effect of 5-fluorouracil by hypoxanthine.

Authors:  M Yoshida; A Hoshi; K Kuretani
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

5.  Effect of N1-(2'-tetrahydrofuryl)-5-fluorouracil and 5-fluorouracil on nucleic acid and protein biosyntheses in Ehrlich ascites cells.

Authors:  S Fujimoto; T Akao; B Itoh; I Koshizuka; K Koyano
Journal:  Cancer Res       Date:  1976-01       Impact factor: 12.701

6.  Selective antagonism of 5-fluorouracil cytotoxicity by 4-hydroxypyrazolopyrimidine (allopurinol) in vitro.

Authors:  P M Schwartz; R E Handschumacher
Journal:  Cancer Res       Date:  1979-08       Impact factor: 12.701

7.  Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.

Authors:  R D Armstrong; R B Diasio
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

8.  Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines.

Authors:  M A Mulkins; C Heidelberger
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

9.  Synthesis and antitumor activity of a series of ftorafur analogues: the effect of varying electronegativity at the 1'-position.

Authors:  M H Holshouser; A M Shipp; P W Ferguson
Journal:  J Med Chem       Date:  1985-02       Impact factor: 7.446

10.  Mechanism of cytotoxicity of 5-fluorouracil: distinction between the irreversible cytotoxic effect of 5-fluorouridine and the reversible cytotoxic effect of 5-fluoro-2'-deoxyuridine on murine lymphoma L5178Y cells in culture.

Authors:  F Kanzawa; A Hoshi; K Kuretani
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.